- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
CBM Market Currents
more »
-
May 4 Life Sciences research firm Cambrex (CBM +13%) pops after its Q1 results easily topped Street estimates late yesterday. Overall revenue rose 14% Y/Y on higher sales of controlled substances and generic active pharmaceutical ingredients. The company also raises sales projections for FY12, now expecting sales to increase between 2% - 6% year-over-year.
Comment![Healthcare, Earnings, On the Move]
CBM in Focus
more »
CBM Related Articles
more »
CBM News
more »
-
at MarketWatch.com (Aug 3, 2011)
-
at MarketWatch.com (Feb 11, 2011)
-
at MarketWatch.com (Feb 11, 2011)
CBM Press Releases and Filings
more »
-
PR Newswire (May 15, 2012)
-
PR Newswire (May 3, 2012)
-
PR Newswire (Apr 27, 2012)
CBM Latest Transcript
more »
-
Wed, May 5, 2010
CBM Cramer
more »
Currently, there are no Cramer articles on CBM.
CBM Instablog posts
more »
CBM vs. ETF Alternatives
Company Description
Currently, there's no company description for CBM.
